Neoplastic progression and prognosis in melanoma

被引:38
作者
Elder, DE [1 ]
VanBelle, P [1 ]
Elenitsas, R [1 ]
Halpern, A [1 ]
Guerry, D [1 ]
机构
[1] UNIV PENN, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA
关键词
D O I
10.1016/S1085-5629(96)80047-2
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Most melanomas evolve through an initial stage known as radial growth phase (RGP), encompassing in situ and microinvasive malignancies in which the probability of cure approaches 100%. At the present time, despite a shift toward earlier recognition of melanoma, by the time of diagnosis roughly 70% of melanomas have evolved to a point, known as vertical growth phase (VGP) or tumorigenic melanoma, at which cure is not certain, and prognosis depends upon certain attributes of the neoplasm and the host. Attempts have been made to assemble these attributes into prognostic models to permit estimation of the probability of cure for individuals and for groups of patients. Attributes that have been identified as independent prognostic variables include thickness of the primary neoplasm, the numbers of mitotic figures, and the presence of tumor-infiltrating lymphocytes (TIL). Other biologically important prognostic variables are on the horizon, and some will likely be based on molecules (markers) expressed on neoplastic cells that show functional significance in mechanisms of metastasis. Copyright (C) 1996 by W.B. Saunders Company.
引用
收藏
页码:336 / 348
页数:13
相关论文
共 94 条
[41]   HOMOZYGOUS DELETIONS WITHIN HUMAN-CHROMOSOME BAND-9P21 IN MELANOMA [J].
FOUNTAIN, JW ;
KARAYIORGOU, M ;
ERNSTOFF, MS ;
KIRKWOOD, JM ;
VLOCK, DR ;
TITUSERNSTOFF, L ;
BOUCHARD, B ;
VIJAYASARADHI, S ;
HOUGHTON, AN ;
LAHTI, J ;
KIDD, VJ ;
HOUSMAN, DE ;
DRACOPOLI, NC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) :10557-10561
[42]  
GUERRY D, 1993, J INVEST DERMATOL, V100, pS342, DOI 10.1038/jid.1993.60
[43]   GROWTH-FACTORS, RECEPTOR KINASES, AND PROTEIN TYROSINE PHOSPHATASES IN NORMAL AND MALIGNANT MELANOCYTES [J].
HALABAN, R ;
FAN, BL ;
AHN, J ;
FUNASAKA, Y ;
GITAYGOREN, H ;
NEUFELD, G .
JOURNAL OF IMMUNOTHERAPY, 1992, 12 (03) :154-161
[44]  
HARRIST TJ, 1984, CANCER, V53, P2183, DOI 10.1002/1097-0142(19840515)53:10<2183::AID-CNCR2820531029>3.0.CO
[45]  
2-9
[46]   BASEMENT-MEMBRANE DEPOSITION IN BENIGN AND MALIGNANT NEVO-MELANOCYTIC LESIONS - AN IMMUNOHISTOCHEMICAL STUDY WITH ANTIBODIES TO TYPE-IV COLLAGEN AND LAMININ [J].
HAVENITH, MG ;
VANZANDVOORT, EHM ;
CLEUTJENS, JPM ;
BOSMAN, FT .
HISTOPATHOLOGY, 1989, 15 (02) :137-146
[47]  
HERLYN M, 1985, J NATL CANCER I, V74, P283
[48]  
HERLYN M, 1993, MOL CELLULAR BIOL ME, P44
[49]   beta 3 integrin expression in melanoma predicts subsequent metastasis [J].
Hieken, TJ ;
Farolan, M ;
Ronan, SG ;
Shilkaitis, A ;
Wild, L ;
DasGupta, TK .
JOURNAL OF SURGICAL RESEARCH, 1996, 63 (01) :169-173
[50]   GERMLINE P16 MUTATIONS IN FAMILIAL MELANOMA [J].
HUSSUSSIAN, CJ ;
STRUEWING, JP ;
GOLDSTEIN, AM ;
HIGGINS, PAT ;
ALLY, DS ;
SHEAHAN, MD ;
CLARK, WH ;
TUCKER, MA ;
DRACOPOLI, NC .
NATURE GENETICS, 1994, 8 (01) :15-21